Moreover, the addition of pembrolizumab to neoadjuvant chemotherapy has significantly improved the pCR rate in MammaPrint ultrahigh (MP2) ER+/HER2− breast cancers in the I-SPY2 trial [17]. The gene discussed is ESR1; the disease is breast cancer.